Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 1;34(5):448-459.
doi: 10.1097/YCO.0000000000000727.

Recent trends in the management of depression in persons with cancer

Affiliations
Review

Recent trends in the management of depression in persons with cancer

Aliza A Panjwani et al. Curr Opin Psychiatry. .

Abstract

Purpose of review: Depression is a prevalent comorbidity in cancer that significantly increases the risk for numerous negative health outcomes. This review updates the current evidence base for management of depression in cancer, highlighting new research directions based on the inflammatory hypothesis of depression.

Recent findings: Research on pharmacotherapy and psychotherapy for depression in cancer has shown mixed efficacy partly because of methodological issues arising from the phenomenology of depression in cancer. After decades of stagnancy, more recent high-quality clinical trials are beginning to provide an evidence base to guide treatment. Inflammatory cytokine-associated depression is a subtype of depression that may have particular relevance in cancer, opening new avenues to explore therapeutic targets and biobehavioral impacts of interventions, which may improve cancer outcomes.

Summary: The continuum of severity in cancer-related depression is important to consider in management approaches. Choice of treatment should be personalized to the patient and their symptom profile as there is currently insufficient evidence to recommend any particular medication or psychotherapy over another. Psychological interventions should be considered first line for mild-to-moderate depression, and pharmacological treatment added for more severe depression, which can be optimally delivered within a collaborative care model.

Video abstract: http://links.lww.com/YCO/A62.

PubMed Disclaimer

Comment in

  • Editorial.
    Isaac M, Filipčić I. Isaac M, et al. Curr Opin Psychiatry. 2021 Sep 1;34(5):445-447. doi: 10.1097/YCO.0000000000000735. Curr Opin Psychiatry. 2021. PMID: 34421111 No abstract available.

References

    1. Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron 2020; 107:234–256.
    1. American Cancer Society. Global cancer facts & figures 4th edition. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-... . (Accessed 10 April 2021)
    1. Howlader N, Noone Am, Krapcho M, et al. . Seer cancer statistics review, 1975-2017 . Available at: https://seer.cancer.gov/csr/1975_2017 . (Accessed 10 April 2021)
    1. Caruso R, Nanni MG, Riba M, et al. Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncol 2017; 56:146–155.
    1. Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 2014; 23:121–130.

Substances